Capvaxive is a vaccine that helps protect adults, and children at higher risk, from pneumococcal disease, including pneumonia and serious blood and brain infections. It is a single shot given into a muscle. It teaches the immune system to recognize 21 types of pneumococcus bacteria.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Capvaxive is a vaccine that protects against pneumococcus (Streptococcus pneumoniae), a common bacterium that causes pneumonia and can spread into the blood (sepsis) or the lining of the brain and spinal cord (meningitis). These deeper infections are called invasive pneumococcal disease. Capvaxive is approved to help prevent invasive disease in adults 18 and older and in children and teens aged 2 through 17 who are at higher risk, and to help prevent pneumococcal pneumonia in adults. In the US, a pneumococcal conjugate vaccine is recommended for all adults 50 and older who have not had one, and for adults 19 to 49 with conditions that raise their risk. Those conditions include a weakened immune system, chronic kidney failure, no working spleen, HIV (human immunodeficiency virus) infection, chronic heart, lung or liver disease, diabetes, smoking, alcohol use disorder, a cochlear implant, or a leak of spinal fluid. Capvaxive is one of the recommended choices, alongside Prevnar 20 and a two-vaccine series that starts with Vaxneuvance and is followed by Pneumovax 23. The "21" refers to the number of pneumococcal types it targets. Its set was chosen around the types that now cause most adult disease: those types caused about 80% of serious pneumococcal infections in US adults recommended for vaccination, and eight of them are not in any earlier vaccine. It leaves out serotype 4, though, which is covered by the other options. In a few places where serotype 4 causes a large share of disease (parts of Alaska, Colorado, New Mexico, Oregon and the Navajo Nation), a clinician may recommend a different vaccine.
Pneumococcus is wrapped in a sugar coating, called a capsule, that helps it hide from the immune system. There are dozens of capsule types (serotypes), and antibodies against one type do not reliably protect against another. Capvaxive contains purified capsule sugars from 21 types. Each sugar is attached to a harmless carrier protein (CRM197, an inactive form of diphtheria toxin), which makes the immune system respond much more strongly than it would to the sugar alone. That is what the word "conjugate" means. After vaccination, the body makes antibodies that coat these bacteria so white blood cells can find and destroy them. The vaccine contains only these purified pieces, not live bacteria. Capvaxive was approved because it produced antibody responses similar to, or for its unique types higher than, those from already licensed vaccines such as Prevnar 20. Its pneumonia approval is an accelerated approval: it rests on these immune-response results, and a confirmatory study is still expected to show that it prevents pneumonia directly. No specific antibody level has been proven to guarantee protection.
Capvaxive is a single 0.5 mL injection into a muscle, given in a clinic or pharmacy. For most adults, one dose completes their pneumococcal vaccination; there is no follow-up shot of Pneumovax 23 as there is with the Vaxneuvance series. Whether and when someone needs it depends on what pneumococcal vaccines they have had before. Adults who got an older vaccine (Prevnar 13 or Pneumovax 23) are generally given Capvaxive at least a year after that dose, or at least five years after if they already had both. Bringing a vaccination record, or letting the pharmacist check a state registry, helps avoid an unnecessary or mistimed dose. Capvaxive can be given at the same visit as other recommended vaccines, such as a flu shot.
Most reactions are mild or moderate and fade within a few days. The most common are a sore arm, tiredness and headache. Muscle aches and redness or swelling where the shot was given are also common. Younger adults report these more often than older adults: in trials, about three in four people aged 18 to 49 had a sore arm, compared with about two in five aged 50 and older. Children may also feel generally unwell or irritable. Some people feel lightheaded or faint shortly after any injection, so sitting for a few minutes afterward is sensible. A serious allergic reaction is rare. Trouble breathing, swelling of the face or throat, widespread hives, or dizziness and weakness after the shot need emergency care right away (call 911).
Capvaxive should not be given to anyone who has had a severe allergic reaction to any of its ingredients or to a vaccine containing diphtheria toxoid, because its carrier protein is related to diphtheria toxin. People with weakened immune systems, including those taking medicines that suppress the immune system, may make fewer antibodies and get less protection. Vaccination is still recommended for them, but the timing relative to treatment may be worth planning with the care team. There is too little information on Capvaxive in pregnancy to know whether it carries any risk. Anyone pregnant or planning pregnancy should discuss timing with their clinician.
Antibody levels in the trials were measured about a month after the shot, so protection builds over the following weeks. The vaccine lowers the chance of serious pneumococcal infection from the types it covers; it does not prevent pneumonia from other bacteria or viruses, and it is not a treatment for an infection already underway. Under current US guidance, adults who receive Capvaxive have finished their pneumococcal series and do not need a booster. Researchers are still tracking how long protection lasts in older adults, so this advice may change. For children and teens at higher risk, Capvaxive was studied as an added dose after they had completed their routine childhood pneumococcal shots, and their pediatrician can say whether it fits their plan.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Capvaxive (Pneumococcal 21-Valent Conjugate Vaccine), what you've noticed, or ask the community a question.